BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 102 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2021. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,826 | -41.8% | 5,166 | +2.4% | 0.00% | – |
| Q2 2023 | $25,482 | +2.3% | 5,046 | -61.7% | 0.00% | – |
| Q1 2023 | $24,920 | -91.1% | 13,185 | -91.5% | 0.00% | -100.0% |
| Q4 2022 | $279,394 | +3.5% | 155,219 | -2.7% | 0.00% | 0.0% |
| Q3 2022 | $270,000 | -31.1% | 159,548 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $392,000 | -86.3% | 159,548 | -84.6% | 0.00% | -83.3% |
| Q1 2022 | $2,867,000 | -48.0% | 1,035,135 | 0.0% | 0.01% | -40.0% |
| Q4 2021 | $5,517,000 | -37.0% | 1,035,135 | 0.0% | 0.01% | -41.2% |
| Q3 2021 | $8,758,000 | -18.0% | 1,035,135 | +18.2% | 0.02% | -15.0% |
| Q2 2021 | $10,678,000 | -49.8% | 875,952 | 0.0% | 0.02% | -51.2% |
| Q1 2021 | $21,251,000 | +10.5% | 875,952 | +46.0% | 0.04% | +5.1% |
| Q4 2020 | $19,230,000 | +34.0% | 600,000 | +26.4% | 0.04% | +14.7% |
| Q3 2020 | $14,351,000 | -28.3% | 474,727 | 0.0% | 0.03% | -32.0% |
| Q2 2020 | $20,014,000 | +100.5% | 474,727 | +18.7% | 0.05% | +72.4% |
| Q1 2020 | $9,980,000 | – | 400,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |